Last reviewed · How we verify
Low dose zonisamide
Low-dose zonisamide reduces seizure activity by blocking sodium and calcium channels while inhibiting carbonic anhydrase.
Low-dose zonisamide reduces seizure activity by blocking sodium and calcium channels while inhibiting carbonic anhydrase. Used for Epilepsy (adjunctive therapy), Partial seizures.
At a glance
| Generic name | Low dose zonisamide |
|---|---|
| Also known as | Low zonisamide |
| Sponsor | Mario Negri Institute for Pharmacological Research |
| Drug class | Anticonvulsant / Antiepileptic agent |
| Target | Voltage-gated sodium channels, T-type calcium channels, carbonic anhydrase |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | FDA-approved |
Mechanism of action
Zonisamide is a sulfonamide anticonvulsant that works through multiple mechanisms: it blocks voltage-gated sodium and T-type calcium channels to reduce neuronal excitability, and inhibits carbonic anhydrase to modulate pH-dependent neural activity. At low doses, these mechanisms provide anticonvulsant effects with potentially improved tolerability compared to standard dosing.
Approved indications
- Epilepsy (adjunctive therapy)
- Potentially Parkinson's disease or other neurodegenerative conditions (investigational at low doses)
Common side effects
- Somnolence
- Ataxia
- Dizziness
- Cognitive impairment
- Nephrolithiasis (kidney stones)
- Hypohidrosis (reduced sweating)
Key clinical trials
- Low vs. Standard Daily Doses of Antiepileptic Drugs in Newly Diagnosed, Previously Untreated Epilepsy(STANDLOW) (PHASE4)
- Low and High Dose Zonisamide in Children as Monotherapy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Low dose zonisamide CI brief — competitive landscape report
- Low dose zonisamide updates RSS · CI watch RSS
- Mario Negri Institute for Pharmacological Research portfolio CI